Evidence map›Paper›PMID 32395681›Full record

ArticleJCO precision oncology2020

P2RY8-CRLF2Fusion-Positive Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Response to Novel Therapy.

Umut Aypar, Justin Taylor, Jacqueline S Garcia, Amir Momeni-Boroujeni, Qi Gao, Jeeyeon Baik, Dory Londono, Ryma Benayed, Allison Sigler, Michael Haddadin and 13 more

Abstract read
In one paragraph

Article in JCO precision oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Interplay between Genetic Ancestry, Self-reported Race and Ethnicity, and Clinical Factors in Pediatric Acute Lymphoblastic Leukemia: A REDIAL Consortium Report.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026
    Article
  2. Journal for immunotherapy of cancer · 2024
    Article
  3. Article
  4. Frontiers in oncology · 2021
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Umut AyparDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Justin TaylorLeukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jacqueline S GarciaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Amir Momeni-BoroujeniDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Qi GaoDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jeeyeon BaikDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Dory LondonoDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ryma BenayedDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Allison SiglerDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Michael HaddadinLeukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Alexander V PensonLeukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Maria E ArcilaDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kerry MullaneyDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Purvil SukhadiaDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Andres E QuesadaDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mikhail RoshalDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nicole CullenDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Ana LakoDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Scott J RodigDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Aaron D GoldbergLeukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Yanming ZhangDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Wenbin XiaoDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Caleb HoDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
XPO1 inhibitors Selinexor and Eltanexor in Combination with Venetoclax and Decitabine (ASTX727) in AMLUM1CA186709 · NCI · DANA-FARBER CANCER INST · PI KEITH T FLAHERTY, DONALD W. KUFE · 2014 to 2026
$25.9M
Defining the Biological and Mechanistic Implications of XPO1 Mutations in Hematologic MalignanciesK08CA230319 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI TAYLOR, JUSTIN · 2018 to 2023
$1.2M
NCI NIH HHS K08 CA230319NCI NIH HHS P30 CA008748NCI NIH HHS UM1 CA186709
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AMLCTLA-4 antagonistimmunotherapyP2RY8-CRLF2 fusion

Identifiers

PMID32395681
PMCPMC7213523

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.